These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

991 related articles for article (PubMed ID: 26366236)

  • 1. Prostate-Specific Antigen (PSA)-Based Population Screening for Prostate Cancer: An Evidence-Based Analysis.
    Pron G
    Ont Health Technol Assess Ser; 2015; 15(10):1-64. PubMed ID: 26366236
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prostate-Specific Antigen (PSA)-Based Population Screening for Prostate Cancer: An Economic Analysis.
    Tawfik A
    Ont Health Technol Assess Ser; 2015; 15(11):1-37. PubMed ID: 26366237
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Screening for prostate cancer.
    Ilic D; Neuberger MM; Djulbegovic M; Dahm P
    Cochrane Database Syst Rev; 2013 Jan; 2013(1):CD004720. PubMed ID: 23440794
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up.
    Andriole GL; Crawford ED; Grubb RL; Buys SS; Chia D; Church TR; Fouad MN; Isaacs C; Kvale PA; Reding DJ; Weissfeld JL; Yokochi LA; O'Brien B; Ragard LR; Clapp JD; Rathmell JM; Riley TL; Hsing AW; Izmirlian G; Pinsky PF; Kramer BS; Miller AB; Gohagan JK; Prorok PC;
    J Natl Cancer Inst; 2012 Jan; 104(2):125-32. PubMed ID: 22228146
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Screening for prostate cancer with the prostate-specific antigen test: a review of current evidence.
    Hayes JH; Barry MJ
    JAMA; 2014 Mar; 311(11):1143-9. PubMed ID: 24643604
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessing contamination and compliance in the prostate component of the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial.
    Pinsky PF; Blacka A; Kramer BS; Miller A; Prorok PC; Berg C
    Clin Trials; 2010 Aug; 7(4):303-11. PubMed ID: 20571134
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of Prostatic-specific Antigen Threshold and Screening Interval in Prostate Cancer Screening Outcomes: Comparing the Swedish and Finnish European Randomised Study of Screening for Prostate Cancer Centres.
    Saarimäki L; Hugosson J; Tammela TL; Carlsson S; Talala K; Auvinen A
    Eur Urol Focus; 2019 Mar; 5(2):186-191. PubMed ID: 28803925
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Eighteen-year follow-up of the Göteborg Randomized Population-based Prostate Cancer Screening Trial: effect of sociodemographic variables on participation, prostate cancer incidence and mortality.
    Hugosson J; Godtman RA; Carlsson SV; Aus G; Grenabo Bergdahl A; Lodding P; Pihl CG; Stranne J; Holmberg E; Lilja H
    Scand J Urol; 2018 Feb; 52(1):27-37. PubMed ID: 29254399
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prostate cancer mortality in the Finnish randomized screening trial.
    Kilpeläinen TP; Tammela TL; Malila N; Hakama M; Santti H; Määttänen L; Stenman UH; Kujala P; Auvinen A
    J Natl Cancer Inst; 2013 May; 105(10):719-25. PubMed ID: 23479454
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Opportunistic testing versus organized prostate-specific antigen screening: outcome after 18 years in the Göteborg randomized population-based prostate cancer screening trial.
    Arnsrud Godtman R; Holmberg E; Lilja H; Stranne J; Hugosson J
    Eur Urol; 2015 Sep; 68(3):354-60. PubMed ID: 25556937
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prostate-Specific Antigen-Based Screening for Prostate Cancer: Evidence Report and Systematic Review for the US Preventive Services Task Force.
    Fenton JJ; Weyrich MS; Durbin S; Liu Y; Bang H; Melnikow J
    JAMA; 2018 May; 319(18):1914-1931. PubMed ID: 29801018
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Finnish prostate cancer screening trial: analyses on the screening failures.
    Kilpeläinen TP; Tammela TL; Malila N; Hakama M; Santti H; Määttänen L; Stenman UH; Kujala P; Auvinen A
    Int J Cancer; 2015 May; 136(10):2437-43. PubMed ID: 25359457
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prostate Cancer Screening in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial: findings from the initial screening round of a randomized trial.
    Andriole GL; Levin DL; Crawford ED; Gelmann EP; Pinsky PF; Chia D; Kramer BS; Reding D; Church TR; Grubb RL; Izmirlian G; Ragard LR; Clapp JD; Prorok PC; Gohagan JK;
    J Natl Cancer Inst; 2005 Mar; 97(6):433-8. PubMed ID: 15770007
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The efficacy of prostate-specific antigen screening: Impact of key components in the ERSPC and PLCO trials.
    de Koning HJ; Gulati R; Moss SM; Hugosson J; Pinsky PF; Berg CD; Auvinen A; Andriole GL; Roobol MJ; Crawford ED; Nelen V; Kwiatkowski M; Zappa M; Luján M; Villers A; de Carvalho TM; Feuer EJ; Tsodikov A; Mariotto AB; Heijnsdijk EAM; Etzioni R
    Cancer; 2018 Mar; 124(6):1197-1206. PubMed ID: 29211316
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Large-scale randomized prostate cancer screening trials: program performances in the European Randomized Screening for Prostate Cancer trial and the Prostate, Lung, Colorectal and Ovary cancer trial.
    de Koning HJ; Auvinen A; Berenguer Sanchez A; Calais da Silva F; Ciatto S; Denis L; Gohagan JK; Hakama M; Hugosson J; Kranse R; Nelen V; Prorok PC; Schröder FH; ;
    Int J Cancer; 2002 Jan; 97(2):237-44. PubMed ID: 11774270
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prostate-Specific Antigen Screening and 15-Year Prostate Cancer Mortality: A Secondary Analysis of the CAP Randomized Clinical Trial.
    Martin RM; Turner EL; Young GJ; Metcalfe C; Walsh EI; Lane JA; Sterne JAC; Noble S; Holding P; Ben-Shlomo Y; Williams NJ; Pashayan N; Bui MN; Albertsen PC; Seibert TM; Zietman AL; Oxley J; Adolfsson J; Mason MD; Davey Smith G; Neal DE; Hamdy FC; Donovan JL;
    JAMA; 2024 May; 331(17):1460-1470. PubMed ID: 38581198
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impacts of a population-based prostate cancer screening programme on excess total mortality rates in men with prostate cancer: a randomized controlled trial.
    van Leeuwen PJ; Kranse R; Hakulinen T; Hugosson J; Tammela TL; Ciatto S; Roobol MJ; Zappa M; de Koning HJ; Bangma CH; Moss SM; Auvinen A; Schröder FH
    J Med Screen; 2013 Mar; 20(1):33-38. PubMed ID: 28075228
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prostate cancer screening practices in a large, integrated health system: 2007-2014.
    Misra-Hebert AD; Hu B; Klein EA; Stephenson A; Taksler GB; Kattan MW; Rothberg MB
    BJU Int; 2017 Aug; 120(2):257-264. PubMed ID: 28139034
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized controlled screening trials for prostate cancer using prostate-specific antigen: a tale of contrasts.
    Rove KO; Crawford ED
    World J Urol; 2012 Apr; 30(2):137-42. PubMed ID: 22116599
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 50.